Sciwind Biosciences, a Chinese drug research and development company for metabolic diseases, announced on Wednesday that it has raised a nearly RMB200 million (US$29.58 million) series A round of financing led by Beijing-based investment firm Legend Capital.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Read 3 Articles for Free with a Basic Account
Gain limited and restricted access to China Money Network.Register Basic Account
Subscribe for an annual subscription for $359
Enjoy comprehensive and exclusive data you can't find elsewhere!Subscribe for $359
Already have an account or paid subscription?